TY  - GEN
AU  - Dummer,Reinhard
AU  - Brase,Jan C
AU  - Garrett,James
AU  - Campbell,Catarina D
AU  - Gasal,Eduard
AU  - Squires,Matthew
AU  - Gusenleitner,Daniel
AU  - Santinami,Mario
AU  - Atkinson,Victoria
AU  - Mandalà,Mario
AU  - Chiarion-Sileni,Vanna
AU  - Flaherty,Keith
AU  - Larkin,James
AU  - Robert,Caroline
AU  - Kefford,Richard
AU  - Kirkwood,John M
AU  - Hauschild,Axel
AU  - Schadendorf,Dirk
AU  - Long,Georgina V
TI  - Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
SN  - 1474-5488
PY  - 2020///0706
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Double-Blind Method
KW  - Drug Resistance, Neoplasm
KW  - drug effects
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Imidazoles
KW  - administration & dosage
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Oximes
KW  - Prognosis
KW  - Proto-Oncogene Proteins B-raf
KW  - genetics
KW  - Pyridones
KW  - Pyrimidinones
KW  - Salvage Therapy
KW  - Skin Neoplasms
KW  - Survival Rate
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(20)30062-0
ER  -